Filtered By:
Management: Food and Drug Administration (FDA)
Countries: India Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Scientists say eye-disease drug may also help fight COVID
FINDINGSAn interdisciplinary research team led by UCLA found that a drug already approved by the Food and Drug Administration for eye disease, verteporfin, stopped the replication of SARS-CoV-2, the virus that causes COVID-19. Their laboratory study identified the Hippo signaling pathway as a potential target for therapies against the coronavirus.BACKGROUNDMany important human biological processes are controlled by complicated chain reactions called signaling pathways, in which certain proteins act as messenger molecules that promote or block the signals of other proteins.The lead researchers were investigating the Hippo...
Source: UCLA Newsroom: Health Sciences - November 8, 2022 Category: Universities & Medical Training Source Type: news
News at a glance: Declining childhood vaccinations, rising ‘superbug’ infections, and a disputed Brazilian fossil
GLOBAL HEALTH
Pandemic contributes to big drop in childhood vaccinations
In what UNICEF Executive Director Catherine Russell called a “red alert,” childhood vaccination rates in many countries worldwide have dropped to the lowest level since 2008, in part because of the COVID-19 pandemic. UNICEF and the World Health Organization together track inoculations against diphtheria, pertussis, and tetanus—which are administered as one vaccine—as a marker for vaccination coverage overall. In 2021, only 81% of children worldwide received the recommended three doses of the combined vaccine, down from 86% in 20...
Source: Science of Aging Knowledge Environment - July 21, 2022 Category: Geriatrics Source Type: research
A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option.
Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial va...
Source: TIME: Health - June 8, 2022 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options.
Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news
What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an *
In the Dragonfly:
*NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open
The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news
Why Countries Around the World Are Suspending Use of AstraZeneca ’s COVID-19 Vaccine
It’s the last thing public health officials want to see in the midst of a pandemic: more than two months after pharmaceutical giant AstraZeneca and Oxford University scientists released their COVID-19 vaccine, countries in Europe and elsewhere are pausing its use amid disconcerting reports that a small number of recipients have experienced blood clots, some of them fatal.
The European Medicines Agency, which oversees drugs and vaccines in Europe, is expected to issue a guidance on March 18 about whether the side effects were related to the vaccine after reviewing the reports; in the meantime, it says the benefits of ...
Source: TIME: Health - March 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Biden ’s Real COVID-19 Challenge Is Restoring a Nation’s Trust in Science
“If the public-health professionals, if Dr. [Anthony] Fauci, if doctors tell us we should take it, I would be first in line. If Donald Trump tells us we should take it, then I’m not taking it.”
That was Vice President-elect Kamala Harris’ response when asked by the moderator of an Oct. 7 debate whether she would get vaccinated against COVID-19. It perfectly captured the politicization of the U.S. response to COVID-19 under the outgoing Trump Administration—and how dangerous that red and blue tinting of the pandemic response has been for the American public. Behaviors like wearing masks and soc...
Source: TIME: Health - November 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme and Alice Park Tags: Uncategorized COVID-19 Source Type: news
Covid-19 Deaths: 1 Million and Surging
Face masks hanging on window bars in Havana, Cuba. Credit: Jorge Luis Baños/IPS By Joseph ChamieNEW YORK, Oct 1 2020 (IPS) Covid-19 deaths worldwide have surpassed 1 million. With new cases of coronavirus infections rapidly mounting again, the numbers of Covid-19 deaths are feared to surge in the coming months.
It took approximately 40 weeks to reach the first million Covid-19 recorded deaths. Some have projected the second million Covid-19 deaths to take about 10 weeks, arriving in late December, and the third million to take an additional 4 weeks, arriving in late January.
Approximately 60 percent of the 1 million Cov...
Source: IPS Inter Press Service - Health - October 1, 2020 Category: International Medicine & Public Health Authors: Joseph Chamie Tags: Global Headlines Health TerraViva United Nations COVID-19 Source Type: news
Diagnosis of SARS-CoV-2: A Review on the Current Scenario and Future Outlook.
Abstract
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undoubtedly created an emerging disease of topmost public health priority spilling throughout the globe. The diagnosis currently relies on a multiplex of criteria including the epidemiology, clinical manifestations and in vitro diagnostics. Presently, the real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) is considered as the most reliable assay for the detection of SARS-CoV-2 and is being supplemented by other auxiliary tests, including serology and radiology. Many of these molecular and immunological tests have b...
Source: Acta Virologica - September 27, 2020 Category: Infectious Diseases Authors: Priyanka, Choudhary OP, Singh I Tags: Acta Virol Source Type: research
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminentl...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
COVID-19 Has Killed Nearly 200,000 Americans. How Many More Lives Will Be Lost Before the U.S. Gets It Right?
Forty-five days before the announcement of the first suspected case of what would become known as COVID-19, the Global Health Security Index was published. The project—led by the Nuclear Threat Initiative and the Johns Hopkins Center for Health Security—assessed 195 countries on their perceived ability to handle a major disease outbreak. The U.S. ranked first.
It’s clear the report was wildly overconfident in the U.S., failing to account for social ills that had accumulated in the country over the past few years, rendering it unprepared for what was about to hit. At some point in mid-September—perha...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alex Fitzpatrick and Elijah Wolfson Tags: Uncategorized Cover Story COVID-19 feature Magazine Source Type: news
